Diagnosis and management of Alzheimer's disease: Past, present and future ethical issues

Progress in Neurobiology

Volumn 110, Issue , 2013, Pages 102-113

  Gauthier, S ^a   Leuzy, A ^a   Racine, E ^b   Rosa Neto, P ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Alzheimer's disease; Diagnosis; Ethical considerations; Treatment

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE; TACRINE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ATAXIC APHASIA; BEHAVIOR DISORDER; BENEFICENCE; COMPREHENSION; CONFIDENTIALITY; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; LIFE EXPECTANCY; LIVER TOXICITY; LIVING WILL; MEDICAL RESEARCH; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PASSIVE IMMUNIZATION; PATIENT CARE; PERSONAL VALUE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRIVACY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REIMBURSEMENT; RESEARCH ETHICS; REVIEW; SENILE PLAQUE; SOCIAL STIGMA; TERMINAL CARE; VERBAL COMMUNICATION; VULNERABLE POPULATION;

4TH CANADIAN CONSENSUS CONFERENCE ON THE DIAGNOSIS AND TREATMENT OF DEMENTIA; A4; AD; ADNI; ALZHEIMER'S DISEASE; ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE; ANTI-AMYLOID; ANTI-AMYLOID TREATMENT OF ASYMPTOMATIC ALZHEIMER'S DISEASE TRIAL; CCCDTD4; CHOLINESTERASE INHIBITORS; CIS; DIAGNOSIS; DIAN; DOMINANTLY INHERITED ALZHEIMER NETWORK; ETHICAL CONSIDERATIONS; FDA; FOOD AND DRUG ADMINISTRATION; INTERNATIONAL WORKING GROUP; IWG; MCI; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MMSE; NATIONAL HOSPICE AND PALLIATIVE CARE ORGANIZATION; NATIONAL INSTITUTE OF AGING/ALZHEIMER ASSOCIATION; NATIONAL INSTITUTE OF NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE AND THE ALZHEIMER'S DISEASE AND RELATED DISORDERS ASSOCIATION; NHPCO; NIA/AA; NINCDS-ADRDA; PEG; PERCUTANEOUS ENDOSCOPIC GASTRONOMY; QOL; QUALITY-OF-LIFE; REVEAL; RISK EVALUATION AND EDUCATION FOR ALZHEIMER'S DISEASE STUDY; SEVERE IMPAIRMENT BATTERY; SIB; TREATMENT; TREATMENT OF ASYMPTOMATIC ALZHEIMER'S DISEASE TRIAL;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; EARLY DIAGNOSIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 84886726315     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2013.01.003     Document Type: Review

References (141)

1. Alzheimer's Association Stigma Cited as a Top Concern for People with Alzheimer's Disease 2008, Available at: Accessed July 27, 2012. http://www.alz.org//news_and_events_14351.sp.
2. Alzheimer's Association, 2008. Voices of Alzheimer's disease: a summary report of the nationwide town hall meetings for people with early stage dementia. Available at: Accessed July 27, 2012. http://www.alz.org/national/documents/report_townhall.pdf.
3. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011, 7:270-279.
4. Alexander M.P. Clinical determination of mental competence. A theory and a retrospective study. Archives of Neurology 1988, 45:23-26.
5. Aminoff B.Z., Adunsky A. Dying dementia patients: too much suffering, too little palliation. The American Journal of Hospice & Palliative Care 2005, 22:344-348.
6. Barnes D.E., Covinsky K.E., Whitmer R.A., Kuller L.H., Lopez O.L., Yaffe K. Predicting risk of dementia in older adults: the late-life dementia risk index. Neurology 2009, 73:173-179.
7. Basting A.D. Forget Memory: Creating Better Lives for People with Dementia 2009, Johns Hopkins University Press, Baltimore.
8. Bateman R.J., Xiong C., Benzinger T.L.S., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Clairns N.K., Xie X., Blazey M., Holtzman D.M., Santacruz A., Buckles V., Olivier A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., SPerlin R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. The New England Journal of Medicine 2012, 367:795-804. for the Dominantly Inherited Alzheimer Network.
9. Beard R.L., Neary T.M. Making sense of nonsense: experiences of mild cognitive impairment. Sociology of Health & Illness 2013, 35:130-146.
10. Beard R.L., Knauss J., Moyer D. Managing disability and enjoying life: how we reframe dementia through personal narratives. Journal of Aging Studies 2009, 23:237-245.
11. Beard R.L., Fox P.J. Resisting social disenfranchisement: negotiating collective identities and everyday life with memory loss. Social Science & Medicine 2008, 66:1509-1520.
12. Behuniak S. The living dead? The construction of people with Alzheimer's disease as zombies. Ageing and Society 2011, 31:70-92.
13. Black S.E., Doody R., Li H., McRae T., Jambor K.M., Xu Y., Sun Y., Perdomo C.A., Richardson S. Donepezil preserves cognition and global function in patients with severe Alzheimer's disease. Neurology 2007, 69:459-469.
14. Bahro M., Silber E., Sunderland T. How do patients with Alzheimer's disease cope with their illness? A clinical experience report. Journal of the American Geriatrics Society 1995, 43:41-46.
15. Burns A., Jacoby R., Luthert P., Levy R. Cause of death in Alzheimer's disease. Age and Ageing 1990, 19:341-344.
16. Callahan C.M., Haag K.M., Buchanan N.N., Nisi R. Decision-making for percutaneous endoscopic gastrostomy among older adults in a community setting. Journal of the American Geriatrics Society 1999, 47:1105-1109.
17. Carlson R.V., Boyd K.M., Webb D.J. The revision of the Declaration of Helsinki: past, present, and future. British Journal of Clinical Pharmacology 2004, 57:695-713.
18. Carrié I., Van Kan A., Gillette-Guyonnet S., Andrieu S., Dartigues J.F., Touchon J., Dantoine T., Rouaud O., Bonnefoy M., Robert P., Cuffi M.N., Bories L., Bordes S., Gasnier Y., Desclaux F., Sudres K., Pesce A., Vellas B. Recruitment strategies for preventive trials: the MAPT Study (Multidomain Alzheimer Preventive Trial). The Journal of Nutrition, Health & Aging 2012, 16:355-359.
19. Carpenter B., Dave J. Disclosing a dementia diagnosis: a review of opinion and practice, and a proposed research agenda. Gerontologist 2004, 44:149-158.
20. Cedarbaum J., Jaros M., Hernandez C., Coley N., Andrieu S., Grundman M., Vellas B. Rationale for the use of the clinical dementia rating sum of boxes as a primary outcome measure for Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2013, 9:S44-S45. ADNI.
21. Christakis N.A., Escarce J.J. Survival of Medicare patients after enrollment in hospice programs. The New England Journal of Medicine 1996, 335:172-178.
22. Cohen D., Eisdorfer C. The Loss of Self 1986, W.W. Norton, New York.
23. Corbett A., Smith J., Ballard C. New and emerging treatments for Alzheimer's disease. Expert Review of Neurotherapeutics 2012, 12:535-543.
24. Corner L., Bond J. The impact of the label of mild cognitive impairment on individual's sense of self. Philosophy, Psychiatry, & Psychology 2006, 13:3-12.
25. Corrigan P.W. How clinical diagnosis might exacerbate the stigma of mental illness. Social Work 2007, 52:31-39.
26. Davis K.L., Thal L.J., Gamzu E.R., Davis C.S., Woolson R.F., Gracon S.I., Drachman D.A., Schneider L.S., Whitehouse P.J., Hoover T.M., Morris J.C., Kawas C.H., Knopman D.S., Earl N.L., Kumar V., Doody R.S. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. The New England Journal of Medicine 1992, 327:1253-1259. and the Tacrine Collaborative Study Group.
27. Draper B., Peisah C., Snowdon J., Brodaty H. Early dementia diagnosis and the risk of suicide and euthanasia. Alzheimer's & Dementia 2010, 6:75-82.
28. Draper B., MacCuspie-Moore C., Brodaty H. Suicidal ideation and the 'wish to die' in dementia patients: the role of depression. Age and Ageing 1998, 27:503-507.
29. Dresser R., Whitehouse P.J. The incompetent patient on the slippery slope. The Hastings Center Report 1994, 24:6-12.
30. Drickamer M.A., Lachs M.S. Should patients with Alzheimer's disease be told their diagnosis?. The New England Journal of Medicine 1992, 326:947-951.
31. Dubois B., Feldman H., Jacova C., DeKosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revisiting the NINCDS-ADRDA criteria. Lancet Neurology 2007, 6:734-746.
32. Erde E.L., Nadal E.C., Scholl T.O. On truth telling and the diagnosis of Alzheimer's disease. The Journal of Family Practice 1988, 26:401-406.
33. Ewbank D.C. Deaths attributable to Alzheimer's disease in the United States. American Journal of Public Health 1999, 89:90-92.
34. Farlow M.R. New treatments in Alzheimer disease and the continued need for placebo-controlled trials. Archives of Neurology 1998, 55:1396-1398.
35. Farlow M., Gracon S.I., Hershey L.A., Lewis K.W., Sadowsky C.H., Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA: the Journal of the American Medical Association 1992, 268:2523-2529.
36. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001, 57:613-620. Donepezil MSAG Study Investigators Group.
37. Fillit H., Hess G., Hill J., Bonnet P., Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009, 73:180-185.
38. Finucane T.E., Christmas C., Leff B.A. Tube feeding in dementia: how incentives undermine health care quality and patient safety. Journal of the American Medical Directors Association 2007, 8:205-208.
39. Fisk J.D., Sadovnick A.D., Cohen C.A., Gauthier S., Dossetor J., Eberhart A., LeDuc L. Ethical guidelines of the Alzheimer Society of Canada. The Canadian Journal of Neurological Sciences 1998, 25:242-248.
40. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975, 12:189-198.
41. Freedman B., Glass K.C., Weijer C. Placebo orthodoxy in clinical research. II: Ethical, legal, and regulatory myths. The Journal of Law, Medicine & Ethics: A Journal of the American Society of Law, Medicine & Ethics 1996, 24:252-259.
42. Freedman B. Equipoise and the ethics of clinical research. The New England Journal of Medicine 1987, 317:141-145.
43. Frierson R.L. Suicide attempts by the old and the very old. Archives of Internal Medicine 1991, 151:141-144.
44. Ganguli M., Rodriguez E.G. Reporting of dementia on death certificates: a community study. Journal of the American Geriatrics Society 1999, 47:842-849.
45. th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Canadian Geriatrics Journal 2012, 15:120-126. on behalf of the CCCDTD4 participants.
46. Gauthier S. Management of Alzheimer's disease using disease-modifying drugs. Neurodegenerative Disease Management 2012, 2:375-378.
47. Gauthier S., Wu L., Rosa-Neto P., Jia J. Prevention strategies for Alzheimer's disease. Translational Neurodegeneration 2012, 1:13-16.
48. Gauthier S. Do we have a treatment for Alzheimer disease? Yes. Archives of Neurology 1999, 56:738-739.
49. Gauthier S., Panisset M. Current diagnostic methods and outcome variables for clinical investigation of Alzheimer's disease. Journal of Neural Transmission. Supplementum 1998, 53:251-254.
50. Gifford F. Community-equipoise and the ethics of randomized clinical trials. Bioethics 1995, 9:127-148.
51. Gillick M.R. Rethinking the role of tube feeding in patients with advanced dementia. The New England Journal of Medicine 2000, 342:206-210.
52. Goffman E. Stigma; Notes on the Management of Spoiled Identity 1963, Prentice-Hall, Englewood Cliffs, N.J.
53. Gordon S.C., Landa D. Disclosure of the genetic risk of Alzheimer's disease. The New England Journal of Medicine 2010, 362:181-182. author reply 2.
54. Graham N., Lindesay J., Katona C., Bertolote J.M., Camus V., Copeland J.R., de Mendonca Lima C.A., Gaillard M., Gély Nargeot M.C., Gray J., Jacobsson K., Kingma M., Kuhne N., O'Loughlin A., Rutz W., Saraceno B., Taintor Z., Wancata J. Reducing stigma and discrimination against older people with mental disorders: a technical consensus statement. International Journal of Geriatric Psychiatry 2003, 18:670-678. Old Age Psychiatry section, World Psychiatric Association, World Health Organization.
55. Green R.C., Roberts J.S., Cupples L.A., Relkin N.R., Whitehouse P.J., Brown T., Eckert S.L., Butson M., Sadovnick D., Quaid K.A., Chen C., Cook-Deegan R., Farrer L. Disclosure of APOE genotype for risk of Alzheimer's disease. The New England Journal of Medicine 2009, 361:245-254. for the REVEAL Study Group.
56. Green S., Davis C., Karshmer E., Marsh P., Straight B. Living stigma: the impact of labeling, stereotyping, separation, status loss, and discrimination in the lives of individuals with disabilities and their families. Sociological Inquiry 2005, 75:197-215.
57. Hanrahan P., Raymond M., McGowan E., Luchins D.J. Criteria for enrolling dementia patients in hospice: a replication. The American Journal of Hospice & Palliative Care 1999, 16:395-400.
58. Hughes J.C. Palliative care in dementia: issues and evidence. Advances in Psychiatric Treatment 2007, 13:251-260.
59. Hughes J.C., Robinson L., Volicer L. Specialist palliative care in dementia. BMJ 2005, 330:57-58.
60. Husband H.J. The psychological consequences of learning a diagnosis of dementia: three case examples. Aging & Mental Health 1999, 3:179-183.
61. Jack C.R., Knopman D.S., Weigand S.D., Wiste H.J., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Rocca W.A., Boeve B.F., Petersen R.C. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology 2012, 71:765-775.
62. Kammoun S., Gold G., Bouras C., Giannakopoulos P., McGee W., Hermann F., Michel J.P. Immediate causes of death of demented and non-demented elderly. Acta Neurologica Scandinavica. Supplementum 2000, 176:96-99.
63. Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer's disease. Neurology 2011, 77:1487-1493.
64. Karlawish J.H., Quill T., Meier D.E. A consensus-based approach to providing palliative care to patients who lack decision-making capacity. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Annals of Internal Medicine 1999, 130:835-840.
65. Karlawish J.H., Whitehouse P.J. Is the placebo control obsolete in a world after donepezil and vitamin E?. Archives of Neurology 1998, 55:1420-1424.
66. Karlawish J.H., Lantos J. Community equipoise and the architecture of clinical research. Cambridge Quarterly of Healthcare Ethics: CQ: the International Journal of Healthcare Ethics Committees 1997, 6:385-396.
67. Kawas C.H., Clark C.M., Farlow M.R., Knopman D.S., Marson D., Morris J.C., Thal L.J., Whitehouse P.J. Clinical trials in Alzheimer disease: debate on the use of placebo controls. Alzheimer Disease and Associated Disorders 1999, 13:124-129.
68. Kitwood T. The dialectics of dementia: with particular reference to Alzheimer's disease. Ageing Society 1990, 10:177-196.
69. Kivipelto M., Ngandu T., Laatikainen T., Winblad W., Soininen H., Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurology 2006, 5:735-741.
70. Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994, 271:985-991.
71. Knopman D., Kahn J., Miles S. Clinical research designs for emerging treatments for Alzheimer disease: moving beyond placebo-controlled trials. Archives of Neurology 1998, 55:1425-1429.
72. Knopman D.S., Morris J.C. An update on primary drug therapies for Alzheimer disease. Archives of Neurology 1997, 54:1406-1409.
73. Kroska A., Harkness S.K. Stigma sentiments and self-meanings: exploring the modified labeling theory of mental illness. Social Psychology Quarterly 2006, 69:325-348.
74. Kukull W.A., Larson E.B., Reifler B.V., Lampe T.H., Yerby M.S., Hughes J.P. The validity of 3 clinical diagnostic criteria for Alzheimer's disease. Neurology 1990, 40:1364-1369.
75. Leber P.D. Hazards of inference: the active control investigation. Epilepsia 1989, 30(Suppl. 1):S57-S63. discussion S4-8.
76. Lecouturier J., Bamford C., Hughes J.C., Francis J.J., Robbie F., Johnston M., Eccles M.P. Appropriate disclosure of a diagnosis of dementia: identifying the key behaviours of 'best practice'. BMC Health Services Research 2008, 8:95.
77. Leuzy A., Gauthier S. Ethical issues in Alzheimer's disease: an overview. Expert Review of Neurotherapeutics 2012, 12:557-567.
78. Link B.G., Phelan J.C. Conceptualizing stigma. Annual Review of Sociology 2001, 27:363-385.
79. Maguire C.P., Kirby M., Coen R., Coakley D., Lawlor B.A., O'Neill D. Family members' attitudes toward telling the patient with Alzheimer's disease their diagnosis. BMJ 1996, 313:529-530.
80. Mann U.M., Mohr E., Gearing M., Chase T.N. Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. Journal of Neurology, Neurosurgery, and Psychiatry 1992, 55(10):956-959.
81. Markle GBt. Telling the diagnosis of Alzheimer's disease. The New England Journal of Medicine 1993, 328:736.
82. Marson D.C. Loss of competency in Alzheimer's disease: conceptual and psychometric approaches. International Journal of Law and Psychiatry 2001, 24:267-283.
83. Marson D.C., Harrell L. Executive dysfunction and loss of capacity to consent to medical treatment in patients with Alzheimer's disease. Seminars in Clinical Neuropsychiatry 1999, 4:41-49.
84. Marson D.C., McInturff B., Hawkins L., Bartolucci A., Harrell L.E. Consistency of physician judgments of capacity to consent in mild Alzheimer's disease. Journal of the American Geriatrics Society 1997, 45:453-457.
85. Marson D.C., Cody H.A., Ingram K.K., Harrell L.E. Neuropsychologic predictors of competency in Alzheimer's disease using a rational reasons legal standard. Archives of Neurology 1995, 52:955-959.
86. Marson D., Annis S., McInturff B., Bartolucci A., Harrell L. Error behaviors associated with loss of competency in Alzheimer's disease. Neurology 1999, 53:1983-1992.
87. Massoud F., Belleville S., Bergman H., Kirk J., Chertkow H., Nasreddine Z., Freedman M. Mild cognitive impairment and cognitive impairment, no dementia: Part B, therapy. Alzheimer's & Dementia 2007, 3:283-291.
88. Mattsson N., Brax D., Zetterberg H. To know or not to know: ethical issues related to early diagnosis of Alzheimer's disease. International Journal of Alzheimer's Disease 2010, 2010:1-4.
89. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
90. McMahon M.M., Hurley D.L., Kamath P.S., Mueller P.S. Medical and ethical aspects of long-term enteral tube feeding. Mayo Clinic Proceedings. Mayo Clinic 2005, 80:1461-1476.
91. Meyers B.S. Telling patients they have Alzheimer's disease. BMJ 1997, 314:321-322.
92. Michon A., Deweer B., Pillon B., Agid Y., Dubois B. Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry 1994, 57:805-809.
93. Miller F.G., Brody H. What makes placebo-controlled trials unethical?. The American Journal of Bioethics: AJOB 2002, 2:3-9.
94. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky St., Morris J.C. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
95. Mitchell S.L., Kiely D.K., Hamel M.B. Dying with advanced dementia in the nursing home. Archives of Internal Medicine 2004, 164:321-326.
96. Mitchell S.L., Berkowitz R.E., Lawson F.M., Lipsitz L.A. A cross-national survey of tube-feeding decisions in cognitively impaired older persons. Journal of the American Geriatrics Society 2000, 48:391-397.
97. Mitchell S.L., Lawson F.M. Decision-making for long-term tube-feeding in cognitively impaired elderly people. CMAJ: Canadian Medical Association Journal 1999, 160:1705-1709.
98. Morris J.C., Cyrus P.A., Orazem J., Mas J., Bieber F., Ruzincka B.B., Gulanski B. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998, 50:1222-1230.
99. National Center for Health Statistics Highlights of a New Report from the National Centre for Health Statistics (NCHS) Mortality Trends for Alzheimer's Disease 1994, Available at:, Accessed August 14, 2012. http://www.cdc.gov/nchs/releases/96facts/fs_alzhe.htm.
100. Novack D.H., Plumer R., Smith R.L., Ochitill H., Morrow G.R., Bennett J.M. Changes in physicians' attitudes toward telling the cancer patient. JAMA 1979, 241:897-900.
101. Okello A., Koivunen J., Edison P., Archer H.A., Turkeimer F.E., Nagren K., Bullock R., Walker Z., Kennedy A., Fox N.C., Rossor M.N., Rinne J.O., Brooks D.J. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009, 73:754-760.
102. Panisset M., Roudier M., Saxton J., Boller F. Severe impairment battery. A neuropsychological test for severely demented patients. Archives of Neurology 1994, 51:41-45.
103. Pepersack T. Disclosing a diagnosis of Alzheimer's disease. Revue Medicale de Bruxelles 2008, 29:89-93.
104. Petersen R.C., Smith G.E., Waring S.C., Imvik R.J., Tangalos E.G., Kokman E. Mild cogntive impairment: clinical characteristics and outcome. Archives of Neurology 1999, 56:303-308.
105. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
106. Porteri C., Galluzzi S., Geroldi C., Frisoni G.B. Diagnosis disclosure of prodromal Alzheimer disease-ethical analysis of two cases. The Canadian Journal of Neurological Sciences 2010, 37:67-75.
107. Post S.G., Whitehouse P.J. Emerging antidementia drugs: a preliminary ethical view. Journal of the American Geriatrics Society 1998, 46:784-787.
108. Post S.G., Whitehouse P.J. Fairhill guidelines on ethics of the care of people with Alzheimer's disease: a clinical summary. Center for Biomedical Ethics, Case Western Reserve University and the Alzheimer's Association. Journal of the American Geriatrics Society 1995, 43:1423-1429.
109. Post S.G. The Moral Challenge of Alzheimer Disease 1995, Johns Hopkins University Press, Baltimore, Md.
110. Pryse-Phillips W. Do we have drugs for dementia? No. Archives of Neurology 1999, 56:735-737.
111. Qizilbash N., Whitehead A., Higins J., Wilcock G., Schneider L., Farlow M. Cholinesterase inhibition for Alzhemer disease. A meta-analysis of the Tacrine trials. JAMA 1998, 280:1777-1782.
112. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. The New England Journal of Medicine 1996, 334:752-758.
113. Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T. Donepezil improves cogntion and global function in Alzheimer disease. Archives of Internal Medicine 1998, 158:1021-1031. and the Donoepezil Study Group.
114. Rohde K., Peskind E.R., Raskind M.A. Suicide in two patients with Alzheimer's disease. Journal of the American Geriatrics Society 1995, 43:187-189.
115. Rothman K.J., Michels K.B. The continuing unethical use of placebo controls. The New England Journal of Medicine 1994, 331:394-398.
116. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging 2010, 31:1275-1283.
117. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
118. Rubin E.H., Kinscherf D.A. Psychopathology of very mild dementia of the Alzheimer type. The American Journal of Psychiatry 1989, 146:1017-1021.
119. Sachs G.A., Shega J.W., Cox-Hayley D. Barriers to excellent end-of-life care for patients with dementia. Journal of General Internal Medicine: Official Journal of the Society for Research and Education in Primary Care Internal Medicine 2004, 19:1057-1063.
120. Sachs G.A. Advance consent for dementia research. Alzheimer Disease and Associated Disorders 1994, 8(Suppl. 4):19-27.
121. Sanders D.S., Carter M.J., D'Silva J., James G., Bolton R.P., Bardhan K.D. Survival analysis in percutaneous endoscopic gastrostomy feeding: a worse outcome in patients with dementia. The American Journal of Gastroenterology 2000, 95:1472-1475.
122. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. The New England Journal of Medicine 1997, 336:1216-1222.
123. Schonwetter R.S., Han B., Small B.J., Martin B., Tope K., Haley W.E. Predictors of six-month survival among patients with dementia: an evaluation of hospice Medicare guidelines. The American Journal of Hospice & Palliative Care 2003, 20:105-113.
124. Shega J.W., Hougham G.W., Stocking C.B., Cox-Hayley D., Sachs G.A. Barriers to limiting the practice of feeding tube placement in advanced dementia. Journal of Palliative Medicine 2003, 6:885-893.
125. Sperling R.A., Aisen P., Beckett L., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2012, 7:280-292.
126. Sperling R., Salloway S., Arrighi M., Morris K., Lu Y., Liu E., Black R., Brashear R.H., Grundman M. Revised estimates of incidence and risk factors for amyloid related imaging abnormalities (ARIA) in the phase 2 studies of bapineuzumab for mild-to-moderate Alzheimer's disease. Alzheimers's & Dementia 2011, 7(Suppl.):e64. http://www.alzheimersanddementia.com/article/S1552-5260(11)02853-6/abstract.
127. Stafford M.C., Scott R.R. Stigma deviance and social control: some conceptual issues. The Dilemma of Difference: A Multidisciplinary View of Stigma 1986, 77-91. Plenum, New York. S.C. Ainlay, G. Becker, L.M. Coleman (Eds.).
128. Summers W.K., Majoveski L.V., Marsh G.M., Tachiki K., Kling A. Oral THA in long-term treatment of senile dementia, Alzheimer type. The New England Journal of Medicine 1986, 315:1241-1245.
129. Temple R., Ellenberg S.S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Annals of Internal Medicine 2000, 133:455-463.
130. Thal L.J., Schwartz G., Sano M., Weiner M., Knopman D., Harrell L., Bodenheimer S., Rossor M., Philpot M., Schor J., Goldberg A. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology 1996, 47:1389-1395.
131. Thompson L.W., Wenger G., Zeuss J.D., Gallagher D. CBT with early stage Alzheimer's disease patients: an exploratory view of the utility of this approach. Alzheimer's Disease-Treatment and Family Stress 1990, 383-397. Hemisphere, New York. E. Light, B.D. Lebowitz (Eds.).
132. United States Food and Drug Administration Approval of a Novel PET Radiopharmaceutical for Amyloid 2012, Available at: Accessed June 15, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202008_Florbetapir_Orig1s000TOC.cfm.
133. Van Dijk P.T., Dippel D.W., Habbema J.D. Survival of patients with dementia. Journal of the American Geriatrics Society 1991 1991, 39:603-610.
134. Varmus H., Satcher D. Ethical complexities of conducting research in developing countries. The New England Journal of Medicine 1997, 337:1003-1005.
135. Wadley V.G., Haley W.E. Diagnostic attributions versus labeling: impact of Alzheimer's disease and major depression diagnoses on emotions, beliefs, and helping intentions of family members. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences 2001, 56:244-252.
136. Watkins P.B., Zimmerman H.J., Knapp M.J., Gracon S.I., Lewis K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271:992-998.
137. Weiner B., Perry R.P., Magnusson J. An attributional analysis of reactions to stigmas. Journal of Personality and Social Psychology 1988, 55:738-748.
138. Whitehouse P.J., Orgogozo J.M., Becker R.E., Gauthier S., Pontecorvo M., Erzigkeit H., Rogers S., Mohs R.C., Bodick N., Bruno G., Dal-Bianco P. Quality-of-life assessment in dementia drug development. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Disease and Associated Disorders 1997, 3:56-60.
139. Winblad B., Kilander L., Eriksson S., Minthon L., Batsman S., Wetterholm A.L., Jansson-Blixt C., Haglund A. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006, 367:1057-1065. Severe Alzheimer's Disease Study Group.
140. Wu L., Rosa-Neto P., Gauthier S. Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. Molecular Diagnosis & Therapy 2011, 15:313-325.
141. Yang-Lewis T., Moody H.R. The forgetful mourner. The Hastings Center Report 1995, 25:32. discussion-3.